Anticalins: inhalable biologicals for severe asthma

这笔拨款旨在开发一种名为“抗菌素”的新型药物。抗菌素的作用类似于一类成功的药物——单克隆抗体（mab）。单克隆抗体太脆弱，体积太大，无法吸入治疗肺部疾病，但抗凝血素体积小，强度大。我们将开发一种抗哮喘药（PRS-060），它可以阻止严重哮喘患者的破坏性免疫反应。通过吸入PRS-060，我们希望为一种常见的控制不佳的严重哮喘制造一种新的临床有用的药物。

This grant aims to develop a new class of medicines called 'anticalins'. Anticalins behave like a successful class of medicines called monoclonal antibodies (mAbs). MAbs are too fragile and large to be inhaled to treat lung disease but anticalins are small and robust. We will be developing an anticalin (PRS-060) which blocks damaging immune reactions in severe asthma. By inhaling PRS-060 we hope to make a new and clinically useful medicine for a common form of poorly-controlled severe asthma.